Contact

Roel Haeseldonckx

Roel Haeseldonckx started his career as a Corporate Credit Manager at Bank J. Van Breda.

During the next 10 years, he built an international career at General Electric (GE) Capital (London, Paris, Brussels, Amsterdam, EMEA) with various leadership positions in Risk Management, Business Development, M&A, Integrations, P&L Leadership and as a member of the management team for Europe, Middle East and Africa (P&L AUM USD 3.2 billion).

In Luxembourg and London he worked as Managing Director and Partner at Mezzanine Investment Funds, including Dam Capital, owned by Anschutz Corporation, one of the world’s largest private companies, where he focused on investing in Mid-Cap companies.

He was a Partner at a leading M&A firm for global midmarket transactions and a Senior Investment Advisor to an independent London and New York based FCA authorized investment manager called Ecofin Ltd.

He was president of the Chicago Booth Alumni Club of Belgium and chairman of its advisory board.

He is a board member of a Luxembourg-based holding company that focuses on maritime sustainable investments.

At General Electric, Roel received the Management Award and two President Awards.

As a Cum Laude MSc in Economics from the Antwerp Business School, he was Erasmus exchanged at the University of Jena in Germany.

He holds a Master’s degree in Corporate Tax from the University of Antwerp Management School and a MBA from the University of Chicago, USA.

His current PhD program at the University of Antwerp focuses on the correlation between enterprise value and sustainability performance.

Roel speaks Dutch, French, German and English.

T: +32 (0) 440 95 76

M: +32 (0)479 745 625

E: roel.haeseldonckx@alexofin.com

CONTACT ROEL

Alexofin bv, trusted Advisory since 2008, Dennenlei 24, 2900 Schoten – BE0894 763 731

OR CONTACT Alexofin USING THE FORM BELOW

Name
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
This field is for validation purposes and should be left unchanged.
Alexofin